Description: XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. Utilizing natural human immunity as a source of new medicines offers the potential to redefine the standards of care for a wide range of diseases. The discovery and manufacturing techniques which enable this were designed by and are exclusive to XBiotech. Headquartered in Austin, Texas, XBiotech also leads the development of innovative, proprietary manufacturing technology to reduce the cost and complexity of biological drug production.
Home Page: www.xbiotech.com
XBIT Technical Analysis
5217 Winnebago Lane
Austin,
TX
78744
United States
Phone:
512 386 2900
Officers
| Name | Title |
|---|---|
| Mr. John Simard | Founder, Pres, CEO & Chairman |
| Ms. Queena Han B.A., C.G.A., CPA, CPA | VP of Fin. & HR and Sec. |
| Dr. Sushma Shivaswamy Ph.D. | Chief Scientific Officer |
| Mr. Benjamín Guzmán | Sr. VP of Corp. Strategy & Fin. |
| Ms. Lisa Simard | Director of Corp. Strategy - XBiotech USA, Inc. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4053 |
| Price-to-Sales TTM: | 11.901 |
| IPO Date: | 2015-04-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 93 |